Good morning, you're tuned into Markets Desk.
Rockwell Automation is putting capital to work for shareholders, with its board authorizing an additional one billion dollars in share repurchases alongside a fresh quarterly dividend declaration. The move signals management confidence in the balance sheet and gives the industrial automation giant meaningful flexibility to return cash as it navigates a mixed demand environment.
Shifting to pharma, Eli Lilly scored a meaningful regulatory win as the FDA approved an every-eight-week maintenance dosing schedule for EBGLYSS, its atopic dermatitis treatment, in patients as young as twelve. That extended interval over the previous every-four-week schedule is a significant convenience upgrade, and on the commercial side it strengthens Lilly's competitive positioning in a crowded but fast-growing dermatology market.
And turning east, Indian equities edged higher in early trade Wednesday even as global markets flashed cautionary signals. The resilience is notable — domestic investors appear willing to look past external headwinds, whether that reflects confidence in India's internal growth story or simply a lack of better alternatives in the current macro landscape remains the question to watch.
That's the tape. Markets Desk, signing off the floor.
